MedTrace Logo

A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

NCT02070289 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-08-18

No results posted yet for this study

Summary

The purpose of this study is to investigate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06372865 for 14 days in healthy subjects of two age groups, 18-55 years (Group 1) and 56-75 years (Group 2).

Conditions

  • Healthy

Interventions

DRUG

PF-06372865

Tablets, 2.5 mg BID, 14 days

DRUG

Placebo

Tablets, BID, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070289 on ClinicalTrials.gov